People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dren Bio, Inc. | — | Biotechnology | Series C | $93.1M | $1.3B | 2022 |
Sakae N. Asanuma at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sakae N. Asanuma on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alex Kolicich | 1 | 8 |
| Rajeev Dadoo | 1 | 7 |
| Sakae Asanuma | 1 | 6 |
| Chandra Leo | 1 | 3 |
| Nenad Tomasevic | 1 | 2 |
| Andrew N. Schiff | 1 | 2 |
| John Wesley | 1 | 2 |
| Ivan Trifunovich | 1 | 1 |
| Rajeev N. Dadoo | 1 | 1 |
| Nenad N. Tomasevic | 1 | 1 |
| Alex N. Kolicich | 1 | 1 |
| Kenneth R Luehrsen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.